Table 2.
Details of included studies.
| First Author, Year | No of pts | MAFLD Definition | Age Years |
BMI kg/m2 |
Female/Male | Treatment/ Control |
Endpoints | |
|---|---|---|---|---|---|---|---|---|
| TG | CG | |||||||
| Abdelbasset et al., 2019 | 15 | 16 | Ultrasound; Diabetes, Obesity |
54.9 | 36.7 | 7/8 | CAEx/UC | ALT, HOMA2-IR, HOMA-IR, BMI, IHTG |
| Abdelbasset et al., 2019 | 16 | 16 | Ultrasound; Diabetes, Obesity |
54.4 | 36.3 | 6/10 | IEx/UC | ALT, HOMA2-IR, HOMA-IR, BMI, IHTG |
| Bacchi et al., 2013 | 14 | 17 | Diabetes | 55.6 | 30.5 | 56 | CAEx/REx | ALT, AST, GGT, BMI |
| Cuthbertson et al., 2016 | 30 | 20 |
1H MRS (>5.3% IHCL); Obesity |
50.0 | 30.7 | 7/23 | CAEx/UC | ALT, AST, GGT, HOMA2-IR, BMI |
| Draz et al., 2019 | 25 | 25 | Ultrasound; Obesity |
30-55 | 37.8 | 25/0 | IEx/EAc | ALT, AST |
| Eckard et al., 2013 | 9 | 11 | Biopsy; Obesity | 52 | 31.3 | 3/6 | CAEx+REx/UC | ALT, AST |
| Hallsworth et al., 2015 | 12 | 11 |
1H MRS (>5% IHTG); Obesity |
54.0 | 31 | N/R | IEx/UC | ALT, AST, GGT, HOMA2-IR, BMI |
| Houghton et al., 2016 | 12 | 12 | Biopsy; Obesity | 54 | IEx+REx/UC | ALT, AST, GGT, HOMA-IR, BMI, IHTG | ||
| Johnson et al., 2009 | 12 | 7 |
1H MRS; Obesity |
49.1 | N/R | CAEx/St | ALT, HOMA2-IR, HOMA-IR, BMI, IHTG | |
| Pugh et al., 2014 | 34 | 20 |
1H MRS (IHTG >5.5%); Obesity |
48 | 31 | 12/22 | CAEx/UC | ALT, AST, GGT, HOMA2-IR, HOMA-IR, BMI |
| Pugh et al., 2013 | 13 | 7 |
1H MRS (IHTG >5.5%); Obesity |
50 | 31 | 6/7 | CAEx/UC | ALT, AST, GGT, BMI |
| Rezende et al., 2016 | 19 | 21 | Biopsy; Obesity |
56.2 | 34.1 | 19/0 | CAEx/UC | ALT, AST, GGT, HOMA-IR, BMI |
| Shamsoddini et al., 2015 | 10 | 10 | Ultrasound; Overweight |
39.7 | 28.1 | 0/10 | CAEx/UC | ALT, AST, HOMA-IR, BMI |
| Shojaee-Moradie et al., 2016 | 15 | 12 | Ultrasound or liver biopsy; Obesity | 52.4 | 31.6 | 0/15 | CAEx+REx/UC | ALT, AST, GGT, BMI |
| Sullivan et al., 2012 | 12 | 6 |
1H MRS (IHTG >10%); Obesity |
48.6 | 37.1 | 8/4 | CAEx/UC | ALT, BMI |
| Zhang et al., 2016 (a) | 66 | 73 | Ultrasound, 1H MRS (>5% IHTG); Overweight |
53.2 | 27.9 | 52/14 | CAEx/UC | ALT, AST, IHTG |
| Zhang et al., 2016 (b) | 69 | 73 | Ultrasound, 1H MRS (>5% IHTG); Overweight |
54.4 | 28.1 | 51/18 | CAEx/UC | ALT, AST, IHTG |
TG, treatment group; CG, control group; BMI, body mass index; CAEx, continuous aerobic exercise; Rex, resistance exercise; IEx, interval exercise; EAc, electroacupuncture; St, stretching; UC, usual care; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; IHTG, intrahepatic triglycerides; HOMA-IR, HOMA2-IR, homeostatic model assessment of insulin resistance; 1H MRS proton magnetic resonance spectroscopy.